All allergic disease ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes all allergic disease ‐ childhood (incidence) compared with human milk feeding ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Food allergy ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes food allergy ‐ childhood (incidence) compared with cow's milk formula ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Cow's milk allergy ‐ infancy (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes cow's milk allergy ‐ infancy (incidence) compared with cow's milk formula ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Cow's milk allergy ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes cow's milk allergy ‐ childhood (incidence) compared with cow's milk formula ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Asthma ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes asthma ‐ childhood (incidence) compared with human milk feeding ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Eczema ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes eczema ‐ childhood (incidence) compared with human milk feeding ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Food allergy ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes food allergy ‐ childhood (incidence) compared with human milk feeding ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Cow's milk allergy ‐ infancy (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes cow's milk allergy ‐ infancy (incidence) compared with human milk feeding ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Cow's milk allergy ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes cow's milk allergy ‐ childhood (incidence) compared with human milk feeding ‐ low‐risk infants (very low certainty).
1 finding from 1 review
All allergic disease ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes all allergic disease ‐ childhood (incidence) compared with cow's milk formula ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Asthma ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes asthma ‐ childhood (incidence) compared with cow's milk formula ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Eczema ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes eczema ‐ childhood (incidence) compared with cow's milk formula ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Bleeding complications: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in bleeding complications: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Intraventricular hemorrhage > Grade II: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in intraventricular hemorrhage > Grade II: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Necrotizing enterocolitis: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in necrotizing enterocolitis: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Sepsis: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in sepsis: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Mortality (all infants): 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in mortality (all infants): 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Hydrocephalus shunt · preterm infants less than three months of age with either: a) IVH demonstrated by ultrasound or computed tomography (CT) scan; or b)…
Repeated lumbar or ventricular punctures showed no clear difference in hydrocephalus shunt compared with conservative treatment (moderate certainty).
1 finding from 1 review